Article Text

Download PDFPDF

Hib vaccination in infants born prematurely
Free
  1. P T Heath1,
  2. R Booy2,
  3. J McVernon3,
  4. J Bowen-Morris3,
  5. H Griffiths3,
  6. M P E Slack4,
  7. A C Moloney5,
  8. M E Ramsay6,
  9. E R Moxon3
  1. 1Department of Child Health and St George’s Vaccine Institute, St George’s Hospital Medical School, London, UK
  2. 2Department of Child Health, Queen Mary College, University of London, UK
  3. 3Oxford Vaccine Group, John Radcliffe Hospital, Oxford, UK
  4. 4PHLS Haemophilus Reference Unit, John Radcliffe Hospital, Oxford, UK
  5. 5Regional Pathology Laboratory, Waterford Regional Hospital, Waterford, Republic of Ireland
  6. 6Communicable Disease Surveillance Centre, Colindale, London, UK
  1. Correspondence to:
    Dr P T Heath, Department of Child Health and St George’s Vaccine Institute, St George’s Hospital Medical School, Cranmer Terrace, London SW17 ORE, UK;
    pheath{at}sghms.ac.uk

Abstract

Aims: To document the immunogenicity and persistence of antibody to polyribosyl-ribitol phosphate (PRP) as well as the clinical protection against invasive Haemophilus influenzae type b (Hib) disease in premature infants immunised at the routine schedule.

Methods: Blood was obtained at 2, 5, 12, and 64 months of age from a cohort of prematurely born infants (≤32 weeks gestation). Anti-PRP antibody concentrations were compared with those of a control cohort of infants born at full term and vaccinated at the same schedule. Hib vaccine failures occurring between October 1992 and October 2000 were reported by paediatricians through an active, prospective, national survey in the UK and Republic of Ireland. The number of prematurely born children with vaccine failure was compared with the corresponding number born at term.

Results: Twenty seven prematurely born infants were followed to 5 years of age. Compared with term infants they had a significantly lower geometric mean concentration of anti-PRP antibody and/or a significantly lower proportion above one or both of the conventional protective antibody concentrations (0.15 and 1.0 μg/ml) at all ages. A total of 165 cases of invasive Hib disease were identified over eight years of national surveillance. Eighteen were premature (<37 weeks); approximately 12 would be expected. The relative risk of UK premature infants developing disease compared with term infants was 1.5 (95% CI 0.9 to 2.6).

Conclusions: Premature infants develop lower antibody concentrations than term infants following Hib conjugate vaccination. Premature infants may also have an increased risk of clinical vaccine failure, but interpretation is limited by the small number of premature infants developing invasive Hib disease over eight years of national surveillance. Overall, vaccination with Hib conjugate vaccines affords a high level of protection to premature babies.

  • Haemophilus influenzae
  • vaccine
  • preterm
  • risk group
  • DTP, diphtheria/tetanus/pertussis vaccine
  • HbOC, PRP conjugated to mutant diphtheria toxoid (CRM197) vaccine
  • Hib, Haemophilus influenzae type b
  • PRP, polyribosyl-ribitol phosphate
  • PRP-OMP, PRP conjugated to outer membrane protein of Neisseria meningitidis vaccine
  • PRP-T, PRP conjugated to tetanus toxoid vaccine
  • ROI, Republic of Ireland
  • TVF, true vaccine failure
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • Atoms
      Nick Mann